Basic Science

SC01 Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory MS Individuals of Different Disability Levels,
SC02 Brain Structural And Functional Abnormalities in Multiple Sclerosis,
SC03 A Comparison of XP23899 With DMF, the Active Ingredient of BG-12,
SC04 The Critical Role of the Toll-like Receptor 2/ Myeloid Differentiation Primary Response Gene (88) Pathway in Danger Signaling and Failure of Myelin Regeneration,
SC05 How Are Relapses, Symptoms and Disease Progression Linked in Early Multiple Sclerosis?,
SC06 Migraine is Comorbid with Multiple Sclerosis in Nationwide Inpatient Sample,
SC07 Characterizing Benign Multiple Sclerosis Using Age, Disease Duration and Disability Status,
SC08 Costimulatory Molecule CD40 is Elevated in Patients with MS,

Cognition, Depression, and Psychosocial

CG01 Social Workers Collaborate to Improve Care for Veterans with MS,
CG02 The MS Social Workers Collaborative of Washington: Sustainable and Thriving at Year 3!,
CG03 Can Demyelinative Lesion in the Brain Cause Behavioral Change?
CG04 Self-Efficacy Improvement in Multiple Sclerosis (SIMS): A Pilot Study,
CG05 An Update on Physical Activity and Cognition in Persons with MS,
CG06 Optical Coherence Tomography Metrics and Third Ventricular Width are Associated with Multiple Sclerosis,
CG07 Prism: A Novel Research Tool to Determine Prevalence of Pseudobulbar Affect,
CG08 A Mother’s Love, Multiple Sclerosis & the Correlation Between Flare Incidences,
CG10 Multiple Sclerosis Presenting as a Focal Cognitive Syndrome,
CG11 Characteristics of Depression Disorders in Multiple Sclerosis,
CG12 A Study to Identify the Psychosocial Needs of Caregivers of Persons with MS,
CG13 The Soul Therapy,
CG14 Computer Practice and Cognitive Functioning in Multiple Sclerosis,
CG15 Cognitive Dysfunction in MS: Education Translates Science Into Practice,
CG16 Subtypes of Depression in Multiple Sclerosis: Phase 1 - Best Evidence Synthesis and Epidemiological Prognosis Framework,
CG17 Addressing the Challenges Faced by Family Caregivers of People with MS,
CG18 Effectiveness of a Psychoeducational Wellness Program in Multiple Sclerosis,
CG19 Health-Related Quality of Life Among People with MS and Urinary Symptoms,
CG20 Productivity Impairment Among People with MS and Urinary Symptoms,
CG21 The Relationship Between Pain and Depression in MS,
CG22 Cognitive Reserve as a Possible Predictor of Cognitive Impairment in People,
CG23 Nursing and Social Work Collaboration: Pioneering Patient Centered Care for...
2012 CMSC Posters

Written by Rachelle Ramirez - Last Updated Thursday, 17 December 2015 16:49

CG24  Negative Feelings Due to Multiple Sclerosis in Caregivers and Patients
CG25  Quality of Life of Elderly Patients with MS
CG26  The 'Long Duration' Multiple Sclerosis Patient: No One Gets Away That Easily
CG27  A Pilot Interdisciplinary Group Cognitive Rehab Intervention for MS: 1-Year Follow-Up
CG28  The Effect of a Creative Art Program on Individuals with Multiple Sclerosis
CG29  MS Depression Screening: Influence on Provider Interventions and Clinical Outcomes
CG30  InMotion: A Phone-Based Intervention to Increase Physical Activity and Improve Mental Health
CG31  Normative Data for the Stroop Color Word Test for a North American Population
CG32  Motor and Neurocognitive Functioning in a Sample of Veterans with Multiple Sclerosis
CG33  The Addition of Biofeedback and Mindfulness Based Training Components to a Psychoeducational Model for a Multiple Sclerosis Support Group

Disease Management, Mechanisms, and Treatment

DX01  Benefit/Risk Evaluation of Multiple Sclerosis Treatments by Patients and Physicians
DX02  Changes in Disability Status in Beta-Interferon Treated Multiple Sclerosis Patients
DX03  What Prompts a Switch in Disease Modifying Therapy Beyond First Line Therapy
DX04  Hospitalizations Among Patients with Multiple Sclerosis
DX05  Challenging Management of Neuromyelitis Optica During Pregnancy
DX06  Clinical Outcomes and Cause of Death in Patients From the 21-Year Long-Term Follow-Up
DX07  Interactive Multiple Sclerosis Self-Paced Nurse Education Program
DX08  fingolimod efficacy by Prior Disease Modifying Therapy Experience: FREEDOMS
DX09  Patient Preferences for Multiple Sclerosis Treatments: TRIBUNE Study
DX10  Interferon Beta-1A Titration Reduces Subjective Flu-Like Symptoms and Fever
DX11  Subcutaneous Interferon Beta-1A Treatment of Pediatric Multiple Sclerosis
DX12  The Multiple Sclerosis Self-Management Workshop
DX13  Rituximab Therapy in Secondary-Progressive Multiple Sclerosis: A Two-Year Follow-Up
DX14  Analysis of First Dose Observation Data for MS Treatment with Fingolimod
DX15  The History of the Vascular Theories of Multiple Sclerosis
DX16  Clinical Aspects of Multiple Sclerosis Patients with Normal Spinal Cord Imaging
DX17  Incidence of Silent Spinal Cord Lesions in Relapsing Remitting Multiple Sclerosis
DX18  T-Cell Subtype in Multiple Sclerosis Patients Treated with Fingolimod
DX19  The Food Critic Who Couldn't Taste and 6 Other Cases of Dysgeusia in Multiple Sclerosis
DX20  Pseudobulbar Affect in MS: Baseline Interrelations in a Study Cohort
DX21  Effects of BG-12 on Magnetic Resonance Imaging Outcomes in the DEFINE Case Report: Progressive Encephalopathy in a Multiple Sclerosis Patient Receiving Natalizumab
DX22  High Risk Syndrome for Neuromyelitis Optica: A Clinical Analysis and Follow-Up
DX23  Association of Neurologic Deficits: Manual Injection vs. Autoinjector Use
DX24  Patient Injection Setting Preferences on an Autoinjector for IFN β-1A
DX25  As Observational Study Examining Factors Affecting Quality of Life in Subjects With Onset of Multiple Sclerosis
DX26  Daclizumab HYP Improves Quality of Life in Multiple Sclerosis Patients
DX27  Fingolimod Slows Brain Volume Loss Regardless of Inflammatory Activity
DX28  Identifying the Needs of Women With Relapsing Remitting MS of Childbearing Age
DX29  Multiple Sclerosis and Huntington's Chorea: a Case Report and Literature Review
DX30  Safety and Tolerability of BG-12 in the Phase 3 CONFIRM Study
DX31  Strive Study: Natalizumab in Anti-JCV Seronegative Patients With Early MS
DX32  Quantifying Neurodegeneration in Multiple Sclerosis White Matter Tracts With
DX34 Cost Sharing and Initiation of Disease-Modifying-Therapy for MS,
DX35 You Are What You Walk: Investigating the Clinical Meaningfulness of the Timed 25 Foot Walk (T25FW),
DX36 Neuromyelitis Optica (NMO) Diagnosed As Syrinx On MRI,
DX37 Establishing a Gilenya Service in Greater Manchester (UK),
DX38 Observations of Patients With Multiple Sclerosis Reporting Endovascular Procedures,
DX39 Misdiagnosis of Initial Neurological Symptoms As Vascular Disease Rather Than Demyelinating Disease,
DX40 Alemtuzumab Improves Quality of Life Compared To IFNB-1A in CARE-MS I,
DX41 Alemtuzumab-Associated Infusion Reactions in CARE-MS I,
DX42 Observations On the Design of Secondary Progressive MS Trials,
DX43 Utilization of Shared Medical Appointment for First Day Observation for Fingolimod,
DX44 A Novel Method of Sharing Practice Patterns: the Mellen Center “Approach”
DX45 Fingolimod Efficacy by Time Since First Symptoms in Phase 3 Studies,
DX46 Patient-Reported Outcomes After Switching To Fingolimod: EPOC Study Design,
DX47 Effect of Fingolimod On the Immune Response To Vaccination,
DX48 How To Improve Patient-Centered Care With Increased Cost Effectiveness,
DX49 Atypical Multiple Sclerosis With Bilateral Internal Jugular Vein Occlusion,
DX50 Multiple Sclerosis After Bariatric Surgery,
DX51 Hospital and ER Use Among Newly Diagnosed Multiple Sclerosis Patients,
DX52 Multiple Sclerosis Patient Treatment With Natalizumab Develops Immune Thrombocytopenia,
DX53 The Gulf War Era Multiple Sclerosis Cohort: Clinical Features At First Diagnosis,
DX54 Rebound Symptoms in Clinically Isolated Syndrome (CIS) Or Multiple Sclerosis,
DX55 NARCOMS: Simple Observation of Relapses Perceived To Be Inferior To Therapy,
DX56 Vitamin D Status in African-American Patients With Multiple Sclerosis: a Cohort Study,
DX57 Cost Effectiveness of Early Versus Delayed Treatment With Fingolimod,
DX58 High Dose Immunosuppressive Therapy (HDIT) With Autologous Hematopoietic Stem Cell Transplantation,
DX59 A One-Year Analysis of Fingolimod Utilization Patterns in Multiple Sclerosis,
DX60 Pegylated Interferon Beta-1a in Relapsing MS: Baseline Characteristics,
DX61 Phase 2 Study of Fingolimod: Efficacy and Safety in Japanese Patients,
DX62 Correlation Between Quality Of Life Measures In Early MS, Physical and Mental Comorbidities in a Managed Care Population With Multiple Sclerosis,
DX63 Impact of Comorbidities On Medical Costs in Health Plan Members With Multiple Sclerosis,
DX64 Daclizumab HYP Reduces Multiple Sclerosis Clinical Disease Activity,
DX65 Adrenocorticotropic Hormone Treatment of Multiple Sclerosis Exacerbations,
DX66 Clinical Importance of Accelerometer Output in Multiple Sclerosis,
DX67 Consistent Efficacy of Fingolimod Across Clinical Development Program,
DX68 Pregnancy, Alphafetoprotein and MS,
DX69 Predictors of Medication Adherence To Fingolimod: An Analysis of Specialty Pharmacy Data,
DX70 Anti-JCV Antibody Status in MS Patients: Baseline Results of STRATIFY-2, Risk Of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy,
DX71 Final Results From the Intramuscular Interferon Beta-1A Pregnancy Registry,
DX72 Safety and Pharmacokinetics of BG-12 Given With and Without Aspirin,
DX73 CCSVI: the Message in Social Media,
DX74 Does Risk Tolerance To MS Therapies Change Over Time? a NARCOMS Survey,
DX75 Effects of BG-12 On Quality Of Life in Relapsing-Remitting MS in DEFINE,
DX76 The Modified Rankin Score Compared To EDSS and MRI Measures in the CCSVI Registry,
DX77 Sustained Long Term Use of Interferon Beta-1A in Patients With Relapsing MS.
DX80  Longitudinal Follow Up of a Cohort of Subjects With Incidental Abnormal MRI At Presentation, poster
DX81  Total Macular Volume and Its Association With Ambulatory Parameters in Person With MS, poster
DX82  The Pacific Northwest MS Registry: Year 4 Update and Diagnosis Validation, poster
DX83  Comparing Rituximab Induction Followed by Glatiramer Acetate To Glatiramer Acetate Alone in Patients With Cognitive Impairment Maintain Good Treatment Adherence With Clinical and Demographic Features of Participants in a VA Longitudinal Study, poster

Rehabilitation
RH01  Mentally Simulated Motor Actions in Neurorehabilitation: A New Protocol for Neurologists treating Multiple Sclerosis, poster
RH02  Effects of a Physical Therapy Reference for Neurologists Treating Multiple Sclerosis on Outcomes in Physical Therapy, A Part of a Multidisciplinary Team for People with Multiple Sclerosis, poster
RH03  Comparison of Actigraph Accelerometers in Persons with MS and Healthy Controls, poster
RH04  Two Conditions of Administering the Six-Minute Walk in Persons with MS, poster
RH05  Effects of a Fall Prevention Initiative on Falls During Outpatient Visits in an MS Clinic, poster
RH06  The Effects of a 6-Minute Endurance Walk on Selected Gait Characteristics and Quality of Life in Patients With Multiple Sclerosis, poster
RH07  Newly Diagnosed Clinic: Emerging Model in MS Care, poster
RH08  Activity Based Rehabilitation May Preserve Function in Multiple Sclerosis, poster
RH09  Impact of a Hip Flexion Assist Device on Gait Performance in MS, poster
RH10  Agreement Between Self-Report and Clinician-Administered EDSS Scores, poster
RH11  Validity and Sensitivity of Spatiotemporal Parameters of Gait in MS, poster
RH12  People with Multiple Sclerosis Show Improved Gait with Balance-Based Training, poster
RH13  Berg Balance Scale Scores in Persons with Multiple Sclerosis are Different in Fatigued vs. Non-Fatigued Conditions, poster
RH14  Validation of Self-Reported Balance and Mobility Measures in Multiple Sclerosis, poster
RH15  Validation of an Abbreviated Activities-Specific Balance Confidence Scale in Multiple Sclerosis, poster
RH16  Walking Impairment and Gait Variability in Multiple Sclerosis, poster
RH17  Whole Limb Vibration Facilitates Magnetic Evoked Potential (MEP) Responses to Targeted Lower Extremity Joint Training Effects on Gait Abnormalities, poster
RH18  Evaluation of a Multiple Sclerosis Educational Track for Physical Therapy Students, poster
RH19  Qualitative Assessment of People with Multiple Sclerosis, poster
RH20  Employment Needs Assessment of People with Multiple Sclerosis, poster
RH22  The Multiple Sclerosis Self-Management Scale: Psychometric Testing, poster
RH23  Weight Status and Disability in Multiple Sclerosis, poster
RH24  Multiple Sclerosis Walking Scale-12 Scores and Gait Parameters, poster
RH25  Neurotronics Walkaide in MS Patients, poster
RH26  Predicting Community Participation in Adults with Multiple Sclerosis, poster
RH27  Dual Task Mobility and Falls Risk in Persons with Multiple Sclerosis, poster
RH28  The Path to Work in People with Multiple Sclerosis, poster
RH29  Tracking Instrumented Gait and Balance in Multiple Sclerosis Over 18 Months, poster
RH30  The Effects of Strength Training Protocols on Fatigue, Strength and Quality of Life In Persons with Multiple Sclerosis, poster
RH31  Physical Activity, Self-Efficacy, and Health-Related Quality of Life In Persons with Multiple Sclerosis, poster
RH32  A Comparison of Balance Training in Multiple Sclerosis: Conventional Training vs. Video Games, poster
RH33  A Comparison of Balance Training in Multiple Sclerosis: Conventional Training vs. Video Games, poster
RH34  A Comparison of Balance Training in Multiple Sclerosis: Conventional Training vs. Video Games, poster
Symptom Management

SX01 Dose-Finding Study of Dextromethorphan/Quinidine for Central Neuropathic Pain
SX02 Evaluation of Provider Referrals to Additional Services for Management of Multiple Sclerosis
SX03 Assessing Quality Measures in Multiple Sclerosis Patients with Initiation of Dalfampridine
SX04 Sustained-Release Fampridine and Mobility in Multiple Sclerosis: Beyond the 25-Foot Walk Test
SX05 Fatigue: Take Control: A VA Multi-Center Randomized Controlled Trial
SX06 Walking Speed and Health-Related Quality of Life in Multiple Sclerosis
SX07 Correlation of Functional Impact of Headaches in an MS Cohort
SX08 Disease Modifying Treatments and Multiple Sclerosis Symptoms
SX09 Office-Based Single-Bolus Intrathecal Baclofen Trials in MS Patients: A Call to Action
SX10 Gilenya® Risk and Support Program (GRASP): A Melbourne Experience
SX11 Participation in Multiple Sclerosis Wellness Programs and Services
SX12 Features in Spontaneous Speech and Conversational Narrative: Comparison with the Belt Than First Thought
SX13 There’s More Hidden Below the Belt Than First Thought
SX14 Treatment Consensus for Flu Like Symptoms During Interferon Therapy for Multiple Sclerosis
SX15 Ampyra Improves Walking and Community Participation in Veterans with Multiple Sclerosis
SX16 Demographic Assessment of Dalfampridine Extended Release Tablets Usage
SX17 Patient or Caregiver Knowledge of Dalfampridine Safety and Use Information
SX18 Prescriber Utilization Study of Dalfampridine Extended Release Tablets
SX19 The Impact of Tobacco Use on Symptoms in Persons with Multiple Sclerosis
SX20 Town Hall Discussions: Information, Support, Growth and Development of Multiple Sclerosis Nurses During Moderated Dialogues
SX21 Prevalence of Asymptomatic Urinary Tract Infections in Persons with Multiple Sclerosis
SX22 Neuromyelitis Optica is Frequently Associated with Severe and Intractable Pain
SX23 Multiple Sclerosis and Spinal Cord Care: Expanding Access and Coordination
SX24 Symptomatic Correlates of Six-Minute Walk Performance in Persons with Multiple Sclerosis
SX25 Migraines in Multiple Sclerosis: Reports from a Multiethnic Cohort